
Inventiva fell 18.2% from $4.06 to $3.32, behind the S&P 500's +11.2%. Its worst day was Jun 2 (−14.3%), and its low came Oct 13 at $2.87.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Inventiva shares rose 10.8%, while the S&P 500 rose 1.0%.
+10.8% · S&P 500 +1.0%
Inventiva shares rose 12.8%, while the S&P 500 rose 0.2%.
Story events cover the past 12 months · Times ET
+12.8% · S&P 500 +0.2%
Inventiva closed at its highest level of the year, 76.1% above where the year started.
+1.3% · S&P 500 0.0%
EPS of $-2.14 missed the $-1.66 estimate on $5.1M revenue (est. $6.0M).
+1.3% · S&P 500 +2.9%
Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steato…
−14.3%, the year's worst day · S&P 500 +0.1%
Inventiva shares rose 16.9%, while the S&P 500 fell 0.5%.
+16.9%, the year's best day · S&P 500 −0.5%
EPS of $-0.29 missed the $-0.20 estimate on $23,251.00 revenue (est. $10.0M).
+4.7% · S&P 500 −0.7%
Inventiva closed at its lowest level of the year, 29.3% below where the year started.
−8.0% · S&P 500 0.0%
Where it ended: a close of $3.32 on Nov 16, 2026.
Nothing in the past 12 months.
All IVA dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IVA and SPY from Benzinga historical bars. Not investment advice.